September 29, 2016 7:03 AM ET

Pharmaceuticals

Company Overview of Bayer HealthCare AG

Company Overview

Bayer HealthCare AG discovers, develops, manufactures, and markets products that help to prevent, diagnose, and treat diseases for humans and animals worldwide. The company operates through four divisions: Animal Health, Consumer Care, Medical Care, and Pharmaceuticals. The Animal Health division produces and distributes various animal health and care products, which include flea and tick-control solutions, anti-infective products, and endoparasitics for farm and companion animals. The Consumer Care division offers over-the-counter products, such as analgesics, gastrointestinal products, dermatological/topical products, cough and cold remedies, and multivitamins and dietary supplements. It s...

Building Q 30

Leverkusen,  51368

Germany

Founded in 1863

Phone:

49 214 301

Fax:

49 214 30 50731

Key Executives for Bayer HealthCare AG

Chairman of Management Board
Age: 54
Chief Financial Officer and Head of Central Administration & Organization
Age: 59
Chief Operating Officer of Bayer CropScience and Member of Executive Committee
Age: 62
Head of Global Drug Discovery
Age: 53
Senior Vice President and Region Head of Consumer Care Division - North America
Compensation as of Fiscal Year 2016.

Bayer HealthCare AG Key Developments

Bayer Healthcare Receives Approval for EYLEA Injection

Regeneron Pharmaceuticals announced that Bayer HealthCare has received European approval for EYLEA (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization. Myopic CNV is an eye disease associated with high degrees of myopia (near-sightedness) and frequently affects people of working age. In a release, the company noted that in the EU, EYLEA is already approved for the treatment of patients with neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, and visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO). In Japan, EYLEA is approved for the treatment of visual impairment due to myopic choroidal neovascularization, age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) and diabetic macular edema.

Regeneron Pharmaceuticals, Inc. and Bayer Healthcare Receive European Approval for EYLEA

Regeneron Pharmaceuticals, Inc. announced that Bayer HealthCare has received European approval for EYLEA (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization. Myopic CNV is an eye disease associated with high degrees of myopi. Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies share equally the profits from sales of EYLEA, except for Japan.

Bayer HealthCare Announces Earnings Results for the Third Quarter and Nine Months of 2015

Bayer HealthCare announced earnings results for the third quarter and nine months of 2015. For the quarter, the company reported sales of EUR 5,651 million compared to EUR 4,740 million a year ago. EBIT was EUR 1,219 million compared to EUR 1,062 million a year ago. EBIT before special items was EUR 1,265 million compared to EUR 1,008 million a year ago. EBITDA was EUR 1,633 million compared to EUR 1,422 million a year ago. EBITDA before special items was EUR 1,677 million compared to EUR 1,368 million a year ago. For the nine months, the company reported sales of EUR 17,063 million compared to EUR 13,724 million a year ago. EBIT was EUR 3,273 million compared to EUR 2,920 million a year ago. EBIT before special items was EUR 3,609 million compared to EUR 2,875 million a year ago. EBITDA was EUR 4,599 million compared to EUR 3,997 million a year ago. EBITDA before special items was EUR 4,908 million compared to EUR 3,948 million a year ago.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bayer HealthCare AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.